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Hospital, Huddinge, SwedenAbstract—Although dopaminergic medication improves
functional mobility in individuals with Parkinson’s disease
(PD), its eﬀects on walking turns are uncertain. Our goals
was to determine whether dopaminergic medication
improves preplanned and unplanned walking turns in indi-
viduals with PD, compared to healthy controls. Nineteen
older adults with mild-to-moderate PD and 17 healthy con-
trols performed one of the following three tasks, presented
randomly: walking straight, or walking and turning 180 to
the right or left. The walking direction was visually cued
before starting to walk (preplanned) or after (unplanned,
i.e., 0.6 m before reaching the turning point). Subjects with
PD were assessed oﬀ dopaminergic medication (OFF) and
on dopaminergic medication (ON) medication. Turning
strategy (step and spin turns), turning performance (turn-
ing distance and body rotation) and walking pattern were
analyzed for three turning steps. Irrespective of medication
state and turning condition, step and spin turns followed a
nearly 50:50 distribution. After intake of dopaminergic med-
ication, subjects with PD increased their turning distance
but not the amount of body rotation or their walking pat-
tern. Compared to controls, turning impairments in sub-http://dx.doi.org/10.1016/j.neuroscience.2016.11.016
0306-4522/ 2016 The Authors. Published by Elsevier Ltd on behalf of IBRO.
This is an open access article under the CC BY license (http://creativecommons.org
*Correspondence to: D. Conradsson, Department of Neurobiology,
Care Sciences and Society, Division of Physiotherapy, Karolinska
Institutet, Alfred Nobels Alle 23, 141 83 Huddinge, Sweden
E-mail addresses: David.conradsson.1@ki.se (D. Conradsson),
Caroline.paquette@mcgill.ca (C. Paquette), Johan.lokk@karolinska.
se (J. Lo¨kk), Erika.franzen@ki.se (E. Franze´n).
Abbreviations: ANOVA, analysis of variance; C7, seventh cervical
vertebrae; CI, conﬁdence interval; ES, eﬀect size; OFF, oﬀ
dopaminergic medication; ON, on dopaminergic medication; PD,
Parkinson’s disease; UPDRS, uniﬁed Parkinson’s disease rating
scale; SD, standard deviation.
18jects with PD remained while ON medication and
problems regulating step width were the most prominent
features of their walking pattern. Speciﬁcally, subjects with
PD turned with narrower cross-over steps, i.e. when the
external foot crossed over the line of progression of the
internal leg. We conclude that turning impairments
remained even after dopaminergic medication and prob-
lems modulating step width appears to be a critical feature
for turning in PD.  2016 The Authors. Published by Else-
vier Ltd on behalf of IBRO. This is an open access article
under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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INTRODUCTION
For individuals with Parkinson’s disease (PD), turning
impairments are common features of gait disturbance
which is, for many, a trigger to freezing of gait, falls and
declined level of societal participation (Stack and
Ashburn, 1999; Bloem et al., 2001; Ashburn et al.,
2008). Even if turning diﬃculties increase with disease
progression, more than 50% of people in mild-to-
moderate stages of PD report turning problems
(Nieuwboer et al., 1998; Bloem et al., 2001). Turning in
PD is characterized by impaired axial coordination
(Crenna et al., 2007; Huxham et al., 2008b; Spildooren
et al., 2013), excessive reduction of spatial gait parame-
ters (Huxham et al., 2008a; Mak et al., 2008) and a
greater number of steps required for turning (Stack and
Ashburn, 2005, 2008; Crenna et al., 2007; Huxham
et al., 2008b). Although the aforementioned studies pro-
vided a detailed description of turning impairments in
PD, this knowledge predominantly reﬂects preplanned
turns, where the walking direction is known in advance.
However, the need to turn in response to a given stimuli,
such as turning to circumvent an unexpected obstacle, is
a common unpredictable condition occurring on a daily
basis. Contrasting preplanned turns, unplanned turning
limits the time for planning and execution of motor com-
mands (Cao et al., 1997; Patla et al., 1999), which have
shown to induce delayed turning onset and degraded per-
formance in individuals with PD compared to controls
(Mak et al., 2008).
Dopaminergic medication has a dramatic clinical
eﬀect on motor impairments in PD (Connolly and Lang,
2014); however the eﬀects of medication on balance
and gait remain uncertain (Bohnen and Cham, 2006;/licenses/by/4.0/).
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ication on global measures of balance (Franzen et al.,
2009; McNeely et al., 2012) and gait in individuals with
PD is well documented (O’Sullivan et al., 1998; Shan
et al., 2001; Morris et al., 2005; McNeely et al., 2012;
McNeely and Earhart, 2013; Curtze et al., 2015); but neg-
ative eﬀects on postural adjustments (Horak et al., 1996;
Hall et al., 2013) and postural sway have also been
reported (Bronte-Stewart et al., 2002; Rocchi et al.,
2002; Franzen et al., 2012; Curtze et al., 2015). Turning
while walking is a complex task incorporating gait and bal-
ance skills, such as deceleration of the forward progres-
sion and maintenance of dynamic body stability while
continuing the step cycle (Patla et al., 1991, 1999). Unfor-
tunately, information about the eﬀects of medication on
walking turns in PD is limited to a few studies focusing
on global performance measures (e.g. turning duration)
only (Akram et al., 2013; Curtze et al., 2015). These
studies revealed inconsistent results that vary from no
improvement (Akram et al., 2013) to moderate
improvements (Curtze et al., 2015). Consequently, little
remains known about the eﬀects of dopaminergic medica-
tion on walking turns (e.g. turning strategies, performance
and regulation of the walking pattern) in individuals
with PD.
Thus, the overarching aim of this study was to
determine whether dopaminergic medication improves
pre- and unplanned turning in individuals with PD.
Speciﬁcally, we sought to assess the eﬀects of
medication on turning initiation (i.e. turning strategy and
onset), turning performance (i.e. body rotation, turning
distance, trajectory and velocity) and the walking pattern
(i.e. step length and width). We hypothesized that
medication would improve turning performance for both
turning conditions, with smaller eﬀects expected for
unplanned turns due to its reactive features requiring
quick modiﬁcation of the walking pattern (Cao et al.,
1997; Mak et al., 2008).Table 1. Participant characteristics
Parkinson’s disease
Age (y) 72 (4)
Gender, males/females 12/7
Body weight (kg) 74.7 (10.7)
Body height (cm) 172.9 (6.4)
Disease duration (y) 5.2 (4.2)
Levodopa dose equivalencya 636 (228)
OFF
UPDRS motor* 44.8 (7.2)
PIGDb,* 3.8 (1.5)
Straight walking
Velocity (m/s) *y 1.17 (0.18)
Step length (m) *y 0.60 (0.07)
Step width (m) 0.08 (0.03)
Values are mean (standard deviation) for all variables except gender that was presented
UPDRS, uniﬁed Parkinson’s disease rating scale; PIGD, Postural Instability and Gait Diﬃ
a Daily levodopa dose equivalency calculated in accordance with Tomlinson et al. (201
b The PIGD score is a four-item sub-score (arising from a chair, standing posture, gait
* Signiﬁcant diﬀerences (p 6 0.025) between the OFF and ON medicated states (Wilco
y Signiﬁcant diﬀerences (p 6 0.025) between the PD ON and the control group (Mann–WEXPERIMENTAL PROCEDURES
Subjects
Nineteen individuals with a clinical diagnosis of idiopathic
PD were recruited from a randomized controlled trial
(Conradsson et al., 2012). We also recruited 17 healthy
individuals, matched for age and gender, as a control
group (Table 1). The sample size of approximately 20
individuals with PD and controls, respectively, was based
on a previous study assessing the eﬀects of dopaminergic
medication on turning (McNeely and Earhart, 2011). The
inclusion criteria for both groups were: age 60 years;
Mini Mental State Examination score of 24 (Folstein
et al., 1975); no visual impairments; and no medical con-
dition or recent injury aﬀecting gait or balance. Speciﬁc
inclusion criteria for PD participants were: currently being
treated with stable oral levodopa therapy; Hoehn and
Yahr stage 2–3; ability to walk indoors without assistance
or a walking aid; and no prior brain surgery, severe dysk-
inesia or freezing of gait. There were no signiﬁcant diﬀer-
ences for any characteristics between the PD group and
the controls (see Table 1). This study was approved by
the Regional Board of Ethics in Stockholm, and all partic-
ipants provided written informed consent prior to their
enrollment in the study.Procedures and setup
The PD group was assessed twice, ﬁrst after overnight
withdrawal of medication (OFF, average oﬀ time = 16 h,
range: 12–22 h) and then approximately one hour after
taking their usual morning dose of dopaminergic
medication (ON). Both test sessions were performed on
the same day, since assessments over two days were
not possible for many of the participants. One trained
physical therapist assessed motor impairments of all
participants before each test session (OFF and ON) by
means of the motor section of the uniﬁed Parkinson’s(n= 19) Control (n= 17)
72 (5)
10/7
76.1 (8.8)
175.8 (8.8)
–
–
ON
35.0 (7.5) –
3.0 (1.4) –
1.24 (0.14) 1.46 (0.15)
0.63 (0.08) 0.76 (0.06)
0.08 (0.03) 0.08 (0.02)
as proportion.
culty.
0).
and postural stability) calculated from the UPDRS motor assessment.
xon signed-rank test).
hitney U test).
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underwent a protocol covering two sessions. In the ﬁrst
session, controls performed the task at comfortable
walking velocity. The same protocol was then repeated
(2nd session) with controls walking at a pace that
matched the comfortable pace of the subjects with PD.
For most control subjects, the matched velocity was
achieved by instructing controls to walk slower than their
comfortable speed. To achieve a matched turning
speed, walking speed was assessed with a handheld
stopwatch and by counting the number of steps over a
distance of two meters prior to the turn. In cases whereFig. 1. (A) Schematic drawing of the walking alley. The walking
direction (straight, right or left) was indicated with a visual signal
before walking initiation during preplanned turns and 0.6 m prior to
the intersection point during unplanned turns. For the three dimen-
sional motion analysis, reﬂective markers were attached to 11
anatomical landmarks to represent the segments of head, trunk,
pelvis and feet. (B) Gray foot prints indicate the two pre-turning steps
and black foot prints represent footstep adjustments for the three
turning steps during a step turn (i.e. ﬁrst turning step equal the turning
direction) and a spin turn (i.e. ﬁrst turning step opposite to the turning
direction). The ﬁrst turning step was identiﬁed as the ﬁrst heel strike
that exceeded two standard deviations in medio-lateral displacement
of straight walking (i.e. gray area in ﬁgure). (C) Calculation of step
width and step length for a right stride.control subjects deviated from the targeted speed, they
were instructed to change their walking speed (i.e. to
walk faster or slower). Subsequently, trials from the
control group were included if their walking velocity
(prior to the intersection positon) was within one
standard deviation (SD) of the mean velocity of the PD
ON. By using this approach turning characteristics could
be compared between PD and the control group without
potential velocity bias (Akram et al., 2010; Spildooren
et al., 2013).
Before the start of data collection, practice sessions
were performed to familiarize participants with the
procedure. The PD and control groups performed two
diﬀerent turning conditions (preplanned and unplanned)
in a randomized order. For both turning conditions,
participants walked at their comfortable velocity along a
9-meter walking lane where the turning position was
indicated by two poles (see circles in Fig. 1A). For both
preplanned and unplanned turns, one of the following
three tasks was performed in a randomized order:
walking straight, or walking and turning 180 to the right
or to the left. Subjects were instructed to walk and turn
to the indicated direction without stopping, taking the
closest path to the target (see squares in Fig 1A).
Subjects started each trial 4.65 m from the turning
intersection, which provided suﬃcient distance to reach
a steady-state straight walking velocity before initiating
the turn (Lindemann et al., 2008). For the preplanned con-
dition, the walking direction was provided by a visual sig-
nal before they started to walk whereas for the unplanned
condition, the same visual signal returned approximately
one step length (0.6 m) prior to the intersection point
(i.e. during steady-state walking). The pre- and unplanned
turning condition each contained a total of 15 trials per
subject (i.e. ﬁve trials – in randomized order – for straight
walking, right and left turning). The participants were
allowed to rest when needed during testing.Measurements
An eight-camera motion analysis system (Elite 2002,
version 2.8.4380; BTS, Milano, Italy) was used to record
at 100 Hz the position of 11 spherical retro-reﬂective
markers located on the spinous process of the seventh
cervical vertebrae (C7) and bilaterally on the head,
acromion, posterior superior iliac spine and heel. Two
markers were also positioned on the two poles forming
the intersection (see Fig. 1A). Three-dimensional
trajectories of the markers were reconstructed using a
tracking system (Tracklab-BTS, Milan, Italy) (Fig. 1A).
Data were processed and ﬁltered (Butterworth low-pass
ﬁlter: 7-Hz cut-oﬀ frequency) using MATLAB software
(MATLAB, 7.4.0, MathWorks, Natick, MA, USA).Data analysis
The outcome variables retained for analysis focused on
turning initiation (i.e. turning strategy and onset), turning
performance (i.e. body rotation, turning distance,
trajectory and velocity) and spatial gait parameters (i.e.
step length and width). We focused our analysis on the
ﬁrst three turning steps since about 75% of the subjects
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D. Conradsson et al. / Neuroscience 341 (2017) 18–26 21with PD reached an 80–120 turn over the ﬁrst three
steps. This turning magnitude is common in daily life
activities (Mancini et al., 2015) and is challenging for PD
(Huxham et al., 2008a).
The turning steps were identiﬁed as the ﬁrst heel strike
exceeding two SD in medio-lateral displacement of ﬁve
straight walking trials (computed for each participant) in
the designated turning direction (see Fig. 1B) (Akram
et al., 2010). Heel strike events were determined based
on the velocity proﬁles of the heel markers (vertical-
axis). Similar to Akram et al. (2010) capturing of the ﬁrst
heel strike event for the right and left foot (i.e. three to four
steps prior to the intersection point for most subjects) was
used as baseline in determining the onset of the ﬁrst turn-
ing step. To discriminate between preparatory turning
steps and the actual turning step, the succeeding turning
step also needed to exceed 2 SD from the straight walk-
ing trial average. As shown by Hase and Stein (1999),
we observed two distinct stepping strategies during turn-
ing. As illustrated in Fig. 1B, a turn was deﬁned as a step
turn if the ﬁrst turning step was performed in the direction
of turning or as a spin turn if the ﬁrst turning step was in
the opposite direction of turning. The proportion of turning
trials using the step strategy was used as an outcome
measure. Turning onset latency was calculated relative
to the intersection point (i.e. time when the trunk [C7 mar-
ker] crossed the intersection point). Therefore, negative
onsets for this outcome measure indicates that turning
was initiated before reaching the intersection point while
positive values reﬂect turns initiated after passing the
intersection.
The magnitude of pelvis rotation at the third turning
step was retained for analysis. For the ﬁrst three turning
steps, the turning distance (i.e. the cumulative linear
displacements of the C7 marker in the horizontal plane),
mean turning velocity (i.e. the ﬁrst derivative of the
tangential displacement of the C7 marker) and mean
turning trajectory (i.e. distance in meters between C7
and the markers positioned at the turning pole) were
calculated. In accordance with Huxham et al. (2006) the
step width and length were calculated by assessing the
spatial position of the heel marker at each heel strikes.
Step width was calculated in relation to the line of progres-
sion for each stride (corresponding to a straight line con-
necting the heel marker between each heel strike) and
measured as the distance between the opposite foot
and the perpendicular line from the line of progression
(see Fig. 1C). Therefore, a negative step width was
obtained when the heel strike of the external foot (e.g.
right foot during a turn to the left) crossed over and landed
medial to the line of progression of the internal leg. As
step length during straight walking was shorter for sub-
jects with PD compared to controls (P= 0.012), the step
length during turning trials were normalized by subtracting
the mean step length of the straight walking trials.
Statistical analysis
All statistical analyses were performed using the
STATISTICA software (Statsoft, version 12, Tulsa, OK).
Responsiveness of turning performance (body rotation,
turning distance, trajectory and velocity) to dopaminergic
Fig. 2. Mean turning onsets (seconds) during pre- and unplanned turning for PD-OFF, PD-ON and
control group. Negative and positive onset values indicate that turning was initiated before and
after crossing the intersection, respectively. Error bars represent 95% conﬁdence interval.
*p 6 0.025.
22 D. Conradsson et al. / Neuroscience 341 (2017) 18–26medication was expressed as
Cohen’s d eﬀect sizes (ES) (Cohen,
1988). Positive ES denote changes
that are considered an improvement
(i.e. toward the control group). A
two-way repeated measures analysis
of variance (ANOVA) was used to
evaluate the eﬀects of medication
(PD OFF and PD ON) and turning
condition (preplanned and unplanned)
on turning initiation (turning strategy
and onset) and turning performance.
A two-way ANOVA was also used to
evaluate the diﬀerence between
groups (PD ON and controls) and
turning condition (preplanned and
unplanned). No diﬀerences were
found between turns to the right or left
or turning strategy (spin or step turn)
for turning onset and performance.
Hoehn and Yahr stages (2–3) were
also similar in these outcomes. Thus, these trials/stages
were collapsed together for further analysis. Furthermore,
as the amplitude of step width and length was diﬀerently
regulated for step and spin turns, both step length and
width were analyzed separately for turning strategies
(step and spin turns) and turning conditions (preplanned
and unplanned). A two-way repeated measures ANOVA
was used to evaluate the eﬀects of medication (PD OFF
and PD ON) and steps (turning step 1, 2 & 3) on step
width and length. A two-way ANOVA was used to evalu-
ate the diﬀerence between groups (PD ON and controls)
and steps (turning step 1, 2 & 3). The Greenhouse–Geis-
ser correction was applied in the event of violations of
sphericity and Tukey’s HSD test whenever a signiﬁcant
interaction eﬀect occurred. Corrections for multiple statis-
tical testing were not used due to the light of criticism of
such corrections (e.g. Bonferroni) to minimize the inci-
dence of false negative when examining hypotheses
(Perneger, 1998). Instead, the signiﬁcance level was set
at p 6 0.025. Data are presented as mean and 95% con-
ﬁdence intervals (95% CI).RESULTS
ON medication, participants with PD improved 22% in
their UPDRS motor score and 21% in their Postural
Instability and Gait Diﬃculty score as compared to OFF
medication (Table 1, P< 0.010). As illustrated in table
1, the mean straight walking velocity improved by
0.07 m/s after medication intake along with a 0.03 m
increase in step length (Table 1, P< 0.010). Still,
individuals with PD ON medication walked slower with
shorter steps as compared to controls (P< 0.001).Turning initiation
Overall, we found a nearly 50:50 distribution between step
and spins during both pre- and unplanned conditions
(Table 2). The strategies used for turning did not change
with medication (PD OFF vs. ON) and were similar
between PD ON and controls. Preplanned turns wereinitiated prior to the intersection while unplanned turns
were initiated after crossing the intersection point (Fig. 2).
Whether OFF or ON medication, subjects with PD
initiated their turns with similar latency. Turning onset
occurred earlier for PD ON (0.16 sec), in contrast to
control subjects in the preplanned condition
(group  condition: P< 0.001); however, no diﬀerence in
onset between groups for the unplanned turns was found.
Turning performance
In both PD and controls, mean turning velocity was at
least twice as high during preplanned turns (0.45–
0.47 m/s), compared to unplanned turns (0.18–0.22 m/s)
(P< 0.001, Table 2). In contrast, the slower unplanned
turns led to a larger degree of body rotation at the third
turning step (100–113) compared to preplanned turns
(77–99) (P< 0.001, Table 2).
Medication increased turning distance by 5% for pre-
and unplanned turns (p= 0.003), still controls
demonstrated 17–19% greater turning distance
compared to PD ON (P< 0.001, Table 2). Medication
did not have any eﬀect on body rotation (P= 0.099),
and controls obtained 10–24% higher body rotation
compared with PD ON (group: P< 0.001). There were
no eﬀects of medication or diﬀerences between PD ON
and controls on turning trajectory and velocity
(P> 0.559). The eﬀects of medication or group (PD ON
and controls) were independent of the type of turn
performed (medication/group  turning condition:
P> 0.132).
Regulation of step width
For PDs and controls, a general pattern of alternating step
width amplitude was observed, i.e. widening – crossing-
over – widening the base of support for step turns and
crossing-over – widening – crossing-over the base of
support for spin turns (Fig. 3A, B).
When using the step strategy during pre- and
unplanned turns, signiﬁcant interaction eﬀects were
found for step width (medication  step interaction:
Fig. 3. Step width (meter) of three turning steps for PD-OFF, PD-ON and control group while
using (A) step and (B) spin turns during the pre- and unplanned condition. Positive values reﬂect
widening of the base of support whereas negative values reﬂect crossing-over of the base of
support (i.e. when the external foot crossed over and landed medial compared to the line of
progression of the internal foot). Error bars represent 95% conﬁdence interval. *p 6 0.025;
**p 6 0.01.
D. Conradsson et al. / Neuroscience 341 (2017) 18–26 23P= 0.024 and P= 0.003, respectively), still post-hoc
testing did not reveal any signiﬁcant diﬀerences
between PD OFF and ON. There were no eﬀects of
medication on step width for the spin strategy.
During step turns control subjects crossed their
external foot further away from the line of progression of
the internal foot compared to PD ON (group  step
interaction: P< 0.001). Speciﬁcally, for the second
turning step using step turns, the step width of controls
was 0.07 m (48–82%) greater (i.e. increased negative
step width) compared to PD ON for both turning
conditions (preplanned: P= 0.016, unplanned:
P= 0.006). For spin turns, the comparison between PD
ON and controls revealed a diﬀerent result for pre- and
unplanned turns. For the unplanned condition, PD ON
did not cross-over as much as controls (group  step
interaction: P< 0.001), which was evident in the 0.07–0.08 m (67%) greater negative step
width in controls for the ﬁrst
(P= 0.001) and third turning step
(P< 0.001). In contrast, there were
no group diﬀerences for the
preplanned condition.Regulation of step length
As illustrated in Fig. 4A, B, both PDs
and controls consistently reduced
their step length in all conditions
during turning, compared to straight
walking. Irrespective of medication
state, subjects with PD
demonstrated a similar reduction of
step length while performing step
and spin turns. Compared to controls
however, PD ON further reduced
their step length by 33–36% using
step turns during the pre- (group:
P= 0.006) and unplanned condition
(group: P= 0.019, Fig. 4A). PD ON
also demonstrated 33% higher step
length reduction for the second
turning step during the unplanned
condition while using spin turns
compared to controls (group  step
interaction: P= 0.004, Fig. 3B).
There were no group diﬀerences for
step length reduction using spin
turns during the preplanned condition.DISCUSSION
This is the ﬁrst study to evaluate the
eﬀects of dopaminergic medication
on pre- and unplanned turns while
walking in individuals with PD. After
intake of dopaminergic medication,
subjects with PD increased the
turning distance but not the amount
of body rotation. Regardless,
dopaminergic medication did not
improve turning performance of
individuals with PD to the level of thecontrol group. These residual turning impairments were
accompanied by narrower, cross-over steps during
turning, which should be considered and addressed
during rehabilitation and in fall prevention programs of
individuals with PD.
Consistent with previous studies (McNeely and
Earhart, 2011; Curtze et al., 2015), turning performance
while on medication did not reach that of the control group.
Our results indicate that these persisting impairments are
related to poor eﬀects of medication on step width and
length. Furthermore, problems regulating step width, not
step length as previously been emphasized in PD
(Hulbert et al., 2014), were the most prominent diﬀerences
between PD and controls in their walking pattern. In partic-
ular, individuals with PD turned with narrower steps while
using a crossing step (i.e. step width closer to a value of
Fig. 4. Mean normalized step length for three turning steps using (A) step and (B) spin turns
during the pre- and unplanned condition for PD-OFF, PD-ON and control group. Step length data
represent the absolute diﬀerence between straight walking and turning, i.e. negative values reﬂect
shorter steps length while turning compared to straight walking. Error bars represent 95%
conﬁdence interval.
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motor task that could induce instability due to the drastic
change of the base of support, but is also an important con-
tributor to body rotation (Huxham et al., 2008a). Conse-
quently, problems modulating step width in PD
compromise medio-lateral stability (Horak et al., 2005;
King and Horak, 2008) and force production necessary to
accelerate the center of mass toward the turn direction
(Mak et al., 2008). In line with our ﬁndings, narrower step
width in PD has been observed during postural reactions
(Horak et al., 2005; King and Horak, 2008) and walking
turns (Huxham et al., 2008a; Mak et al., 2008). It is likely
that problems modulating step width restrict the perfor-
mance of turning, as seen in our data, and lead to instability
and falls in individuals with PD during everyday living. As
previously suggested by King and Horak (2008), this ﬁnd-
ing highlights the importance of targetingmedio-lateral sta-
bility during rehabilitation sessions in individuals with PD.Walking turns involve an
interaction between the linear
component (i.e. forward progression
of the body) and the angular
component (i.e. rotation in relation to
the longitudinal axis) (Goodworth
et al., 2012). Our results showed bet-
ter responsiveness to dopaminergic
medication for the linear component
compared to the angular component
of turning. Although previous ﬁndings
reporting similar eﬀects of dopaminer-
gic medication on the performance of
turning-in-place (Franzen et al., 2009;
McNeely and Earhart, 2011) and
walking turns in individuals with PD
(Curtze et al., 2015), the divergent
eﬀect of medication on linear and
angular components of walking is a
novel ﬁnding. Increased functional
connectivity between cortical and
sub-cortical brain areas has been
demonstrated during turning com-
pared to straight walking in PD (Gilat
et al., 2015). Our current ﬁndings
imply that the linear and angular com-
ponent of locomotion likely involve
distinct brain networks with potential
varying sensitivity to dopaminergic
medication. This notion is also sup-
ported by a recent study of Curtze
et al. (2015) reporting smaller eﬀects
of dopaminergic medication on walk-
ing turns (ES = 0.20–0.50) compared
to straight walking (ES > 0.50).
In contradiction to our hypothesis,
the eﬀects of medication on turning
performance were not inﬂuenced by
the availability of time for planning
the turn (i.e. pre- vs. unplanned
condition). Less eﬀects of medication
were expected for the unplanned
turns because of their more reactive
nature requiring quick modiﬁcation ofthe walking pattern (Cao et al., 1997), which adds stress
to impaired executive functioning in PD (i.e. rapid informa-
tion processing to regulate the motor commands)
(Dirnberger and Jahanshahi, 2013). Impaired executive
functioning has shown to be ineﬀectively treated with
dopaminergic medication in individuals with PD (Michely
et al., 2012). On the other hand, the unplanned turn was
triggered and guided by a visual cue, which by itself could
have facilitated turning as previously reported for other
tasks (Mak and Hui-Chan, 2005; Nieuwboer et al., 2009).
We aimed to capture realistic turning behavior without
spatial restrictions and found a nearly 50:50 distribution
between step and spin turns. This ﬁnding is in contrast
to previous studies of healthy adults in that spin turns
were more common during preplanned turns (Akram
et al., 2010), while step turns have shown to be more
common during challenging turns (e.g. unplanned turns)
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overall mixed pRef. between step and spin turns found
in the present study could represent a sustained ﬂexible
repertoire of movement strategies. Furthermore, turning
was initiated in a similar manner whether OFF or ON
medication; however, the control group initiated their turn
64% later during preplanned turns compared to PD ON.
This ﬁnding may be a compensatory strategy adopted
by individuals with PD in accounting for the poor respon-
siveness of dopaminergic medication to turning we
observed, or because of balance impairments or diﬃcul-
ties with modifying an ongoing motor command (Chong
et al., 2000; Mak et al., 2008).
This study aimed to determine whether dopaminergic
medication improves turning in individuals with mild-to-
moderate PD who do not present with freezing of gait.
Therefore, these results can only be generalized to this
speciﬁc population. Still, as turning is an important
factor in triggering freezing of gait episodes, future
studies should investigate the eﬀects of medication on
turning in individuals who report freezing of gait. All
subjects with PD were tested on the same day and in a
ﬁxed order (OFF ﬁrst), which may have led to an
underestimation of the medication eﬀect (e.g. fatigue) or
to an overestimation induced by a practice eﬀect from
repeated testing. Thus, to address the potential risk of
fatigue and a practice eﬀect, brief resting sessions were
allowed during testing and practice sessions were
performed prior to testing, respectively. Further –
contradicting a practice eﬀect – turning performance did
not systematically improve across the number of trials in
PD OFF and ON (data not reported). Furthermore, while
all subjects with PD were conﬁrmed responders to
dopaminergic medication (indicated by improved
UPDRS-motor, PIGD score and straight line walking),
the level of responsiveness to medication was not an
inclusion criterion, as in other studies (McNeely and
Earhart, 2011; McNeely et al., 2012). This may limit the
generalization and interpretation of these results. Finally,
in contrast to several previous studies of turning in PD
(Mak et al., 2008; Akram et al., 2013; Curtze et al.,
2015), the controls’ walking velocity was matched to that
of the PD subjects. Thus, the diﬀerences we observed in
turning with PD are attributed to the disease itself rather
than walking speed.
CONCLUSIONS
Dopaminergic medication appears to increase turning
distance but not the amount of body rotation irrespective
of performing preplanned or unplanned walking turns.
Turning impairments in individuals with PD on
dopaminergic medication did not reach the performance
of the control group. These residual turning impairments
in individuals with PD were accompanied by narrower
cross-over steps during turning. These narrower steps
reduce stability and are therefore considered as
important targets of rehabilitation in individuals with PD.
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